RECKITT BENCKIS/S (RBGLY) Upgraded to “Hold” at Zacks Investment Research

RECKITT BENCKIS/S (OTCMKTS:RBGLY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Friday.

According to Zacks, “Reckitt Benckiser Group Plc engages in manufacturing and distributing household, toiletry, pharmaceutical and food products. The company offers antiseptic liquids, depilatory products, medicated sore throat products, condoms, cold/flu products, acne treatment products, analgesics and upper gastro-intestinal products, foot care and comfort footwear products, denture care and dry skin care products, fabric care products, surface care products and polishes/waxes. Reckitt Benckiser Group is based in Slough, the United Kingdom. “

A number of other research firms also recently commented on RBGLY. BNP Paribas upgraded shares of RECKITT BENCKIS/S from a “neutral” rating to an “outperform” rating in a research report on Tuesday, November 20th. Jefferies Financial Group downgraded shares of RECKITT BENCKIS/S from a “hold” rating to an “underperform” rating in a research report on Thursday, January 24th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold”.

RBGLY stock opened at $15.60 on Friday. RECKITT BENCKIS/S has a 52 week low of $14.64 and a 52 week high of $18.67. The stock has a market cap of $55.93 billion, a price-to-earnings ratio of 17.33, a P/E/G ratio of 4.98 and a beta of 0.95. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.50 and a current ratio of 0.68.


Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Featured Article: Do stock splits help investors?

Get a free copy of the Zacks research report on RECKITT BENCKIS/S (RBGLY)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for RECKITT BENCKIS/S (OTCMKTS:RBGLY)

Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit